News
-
Semaglutide Myths: 10 Claims Checked
Ten common semaglutide claims, checked against clinical trials, current prescribing information, and FDA findings.
-
Tesamorelin Clinical Trials: What the Studies Show
The large trials found less visceral abdominal fat in adults with HIV-associated lipodystrophy. They did not test general weight loss, anti-aging, or the compounded formulations sold today.
-
Tirzepatide Injection Site Reaction: What to Know
A small red, itchy, sore patch or raised spot can be a tirzepatide injection site reaction. The Zepbound label reports these reactions in 6% to 8% of treated adults, but a spreading or whole-body reaction is a different concern.
-
20 Percent Weight Loss: What the Numbers Show
Twenty percent weight loss is 40 pounds from a 200-pound starting weight. In two large trials, that headline also came with changes in waist size, blood pressure and lab results—but it was an average, not a promise.
-
Who Discovered GHRH? The Two 1982 Teams
Two independent teams identified GHRH in 1982, using an unexpected clue from pancreatic tumors. Their papers opened the path to sermorelin, tesamorelin and CJC-1295.
-
MOTS-c Exercise Claims: What the Studies Show
MOTS-c is called an exercise mimetic because exercise raises it in people and administered MOTS-c changed running performance in mice. No published human trial shows that taking it improves a workout.
-
Does Semaglutide Increase Heart Rate?
Yes, semaglutide can raise resting heart rate by a few beats per minute on average. A steady rise or a racing heartbeat at rest deserves a closer look, because an average cannot explain one person's symptoms.
-
Should I Take Tirzepatide? How a Provider Decides
Should I take tirzepatide? It may fit when weight is affecting health, but a BMI number alone cannot answer the question. A provider weighs the goal, medical history, past GLP-1 experience and practical access together.
-
SURMOUNT-2 Results: What the Trial Found
SURMOUNT-2 followed 938 adults with obesity or overweight and type 2 diabetes for 72 weeks. Average weight change was -12.8% and -14.7% with tirzepatide, compared with -3.2% with placebo.
-
Does Tirzepatide Cause Low Blood Sugar?
Tirzepatide can cause low blood sugar, but it was uncommon in trials of people without diabetes. The risk rises when insulin or a sulfonylurea is also part of treatment.
-
Wegovy Prescribing Information, Explained
The current Wegovy label is revised June 2026. It covers weight, cardiovascular and MASH uses; the injection dose ladder including 7.2 mg; the boxed warning; common reactions; pregnancy; and device formats.
-
Who Discovered TB-500? The Full Story
The short answer starts with Teresa Low, Shu-Kuang Hu, and Allan Goldstein, who sequenced thymosin beta-4 in 1981. The seven-amino-acid fragment now called TB-500 came later, and the record does not name one inventor.
-
5 Percent Weight Loss Benefits: Study Numbers
Five percent can be a meaningful first milestone. Here's what studies measured in blood sugar, blood pressure, and sleep, and where the numbers stop being a useful prediction.
-
BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-
Does Semaglutide Cause Headaches? The Facts
Headache is a recognized side effect, but the timing alone doesn't explain it. The trial rates, possible triggers, and symptoms that need prompt care.
-
SELECT Trial Semaglutide Results: What 20% Means
SELECT recorded fewer major heart and blood-vessel events with branded semaglutide. Here is what the 20% headline means, who was studied, and where the evidence stops.
-
Semaglutide and Antidepressants: Can They Mix?
An antidepressant alone does not rule out semaglutide. The useful questions are how tablets are absorbed, how mood is doing, and what each medicine means for weight.
-
Should I Take Semaglutide? How a Provider Decides
A BMI of 32 can open the conversation. Medical history, current medicines and a workable follow-up plan determine where it goes.
-
Who Discovered Kisspeptin? The People Behind It
Danny Welch's cancer research started the story in 1996. Other teams found the peptide, connected it to puberty, and brought it into human studies.
-
BPC-157 Myths: 10 Claims Checked
Ten familiar claims about BPC-157, graded against the studies: what comes from rats, what has been observed in people, and what remains unknown.
Page 2 of 18 · 344 articles